Press Releases | Educators Post Observer

Explore more publications!

Press Releases

Materials science joins ESI Global Top 1%

January 12, 2026

Materials science joins ESI Global Top 1%

Xi'an Jiaotong-Liverpool University

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

January 12, 2026

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

GlobeNewswire, Inc.

January 12, 2026

Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters

GlobeNewswire, Inc.

January 12, 2026

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

GlobeNewswire, Inc.

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

January 12, 2026

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

GlobeNewswire, Inc.

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

January 11, 2026

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

GlobeNewswire, Inc.

January 12, 2026

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

GlobeNewswire, Inc.

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

January 12, 2026

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

GlobeNewswire, Inc.

January 12, 2026

NexGold Provides Summary of 2025 Activities and Key Priorities for 2026

GlobeNewswire, Inc.

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

January 12, 2026

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

GlobeNewswire, Inc.

Best Titanium Cutting Board for 2026: Microplastic Research and Material Analysis Shape Consumer Kitchen Decisions — TIBO

January 10, 2026

Best Titanium Cutting Board for 2026: Microplastic Research and Material Analysis Shape Consumer Kitchen Decisions — TIBO

GlobeNewswire, Inc.

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

January 12, 2026

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

GlobeNewswire, Inc.

Stallion Uranium Refines Coyote Target with Highly Conductive Anomalies from Ground EM Survey, Mobilizes Stone Island VTEM Survey

January 12, 2026

Stallion Uranium Refines Coyote Target with Highly Conductive Anomalies from Ground EM Survey, Mobilizes Stone Island VTEM Survey

GlobeNewswire, Inc.

January 12, 2026

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

GlobeNewswire, Inc.

Teachally Named 2026 Top EdTech for Curriculum and Instruction by District Administration

January 8, 2026

Teachally Named 2026 Top EdTech for Curriculum and Instruction by District Administration

GlobeNewswire, Inc.

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

January 12, 2026

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

GlobeNewswire, Inc.

January 12, 2026

Pharvaris Outlines 2026 Strategic Priorities

GlobeNewswire, Inc.

Mereo BioPharma Provides Corporate Update

January 12, 2026

Mereo BioPharma Provides Corporate Update

GlobeNewswire, Inc.

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

January 12, 2026

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

GlobeNewswire, Inc.

January 9, 2026

Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity

GlobeNewswire, Inc.